January 29, 2021
A Manhattan federal judge gave an initial nod to a $3 million settlement that would end investor claims that biopharmaceutical company Nabriva Therapeutics PLC and four of its executives misrepresented the company's prospects for getting federal approval for a new antibiotic.
April 28, 2020
A Manhattan federal judge on Tuesday threw out a putative class action against Nabriva Therapeutics, ending allegations that the biopharmaceutical company misrepresented its prospects of getting federal approval for a new drug.
May 09, 2019
Nabriva Therapeutics misled shareholders into thinking it was about to get federal approval for a new drug when company executives knew it actually wouldn't because of substandard manufacturing conditions, according to a proposed class action filed in New York federal court.